Rina-S: Clinical Trials

7 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 3, 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	6	Recruiting 4, Active not recruiting 1, Not yet recruiting 1
Phase 2	3	Recruiting 3
Phase 1	1	Recruiting 1

Follow Rina-S: new trials by email Literature Review of Rina-S trials Research Report on Rina-S

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer	Phase 3	Not yet recruiting	Genmab	602	2026-11-01	2026-10-05
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	688	2026-08-28	2026-11-04
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer	Phase 3	Recruiting	Genmab	82	2026-06-26	2026-11-03
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers Rina-S - Gastrointestinal Cancers	Phase 2	Recruiting	Genmab	160	2026-05-11	2026-11-03
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer	Phase 3	Recruiting	Genmab	544	2026-04-03	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer Rina-S - Non-small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Genmab	240	2026-01-30	2026-11-03
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer Rina-S, IC - Endometrial Cancer, Recurrent or Progressive Endometrial Cancer	Phase 3	Recruiting	Genmab	660	2025-11-28	2026-11-03
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer	Phase 3	Active not recruiting	Genmab	584	2025-02-07	2026-11-03
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer	Phase 1 / Phase 2	Recruiting	Genmab	952	2022-12-07	2026-11-04

Conditions studied

Ovarian Neoplasms (6)  ·  Fallopian Tube Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Endometrial Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Gastrointestinal Neoplasms (1)  ·  Mesothelioma (1)  ·  Recurrence (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)  ·  Uterine Neoplasms (1)

Sponsors

Genmab (9)

Countries

Japan (7)  ·  United States (7)  ·  Belgium (5)  ·  France (5)  ·  Spain (5)  ·  Australia (4)  ·  China (4)  ·  Germany (4)  ·  Poland (4)  ·  Finland (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Norway (3)  ·  South Korea (3)  ·  Canada (2)

NIH funding

2025 (4)